GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » EV-to-FCF

Paion Ag (Paion Ag) EV-to-FCF : -1.33 (As of May. 17, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Paion Ag's Enterprise Value is $18.33 Mil. Paion Ag's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-13.78 Mil. Therefore, Paion Ag's EV-to-FCF for today is -1.33.

The historical rank and industry rank for Paion Ag's EV-to-FCF or its related term are showing as below:

PAIOF' s EV-to-FCF Range Over the Past 10 Years
Min: -64.22   Med: -3.34   Max: 160.03
Current: -1.31

During the past 13 years, the highest EV-to-FCF of Paion Ag was 160.03. The lowest was -64.22. And the median was -3.34.

PAIOF's EV-to-FCF is ranked worse than
100% of 521 companies
in the Drug Manufacturers industry
Industry Median: 24.13 vs PAIOF: -1.31

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Paion Ag's stock price is $0.0251. Paion Ag's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.978. Therefore, Paion Ag's PE Ratio for today is At Loss.


Paion Ag EV-to-FCF Historical Data

The historical data trend for Paion Ag's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag EV-to-FCF Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.41 -40.56 158.39 -2.48 9.28

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.05 -2.48 - 9.28 -

Competitive Comparison of Paion Ag's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paion Ag's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Paion Ag's EV-to-FCF falls into.



Paion Ag EV-to-FCF Calculation

Paion Ag's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=18.325/-13.782
=-1.33

Paion Ag's current Enterprise Value is $18.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion Ag's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-13.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion Ag  (OTCPK:PAIOF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Paion Ag's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0251/-2.978
=At Loss

Paion Ag's share price for today is $0.0251.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion Ag's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.978.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Paion Ag EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Paion Ag's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.